PathAI and ConcertAI on Tuesday announced a strategic partnership to launch a quantitative histopathology and curated clinical real-world data (RWD) solution that combines PathAI’s PathExplore tumor microenvironment panel with ConcertAI's Patient360 and RWD360 multimodal clinical data products.
PathAI specializes in artificial intelligence (AI)-enabled pathology solutions; ConcertAI specializes in AI software as a service (SaaS) for healthcare and the life sciences.
"Analysis of tumor microenvironment characteristics is critical to understanding why certain patients respond to a specific therapy and others do not," Jeff Elton, PhD, CEO of ConcertAI, said in a statement. "It further allows the definition of clinical strategies that might increase the numbers of patients benefiting from current medicines and improve the effectiveness of new ones."
In the collaborative solution, PathExplore extracts quantitative measures of the tumor microenvironment known as human interpretable features (HIFs) from whole-slide images of real-world H&E-stained samples from PathAI's pathology laboratory. These data are linked to Patient360's electronic medical record (EMR), medical claims, and Social Determinants of Health data, and to RWD360, which provides scaled insights from structured EMR data, medical claims, and Social Determinants of Health for large populations.
A histopathology dataset comprising patient-level and population-level real-world data allows for greater insights into treatment dynamics and standards of care on both scales, the companies said.
"Our collaboration with ConcertAI will offer access to a uniquely linked quantitative pathology dataset, allowing researchers to explore hypotheses far beyond the scope of small, controlled datasets, such as identifying and analyzing novel histological biomarkers correlated with patient treatment and outcomes," Andy Beck, CEO and co-founder of PathAI, said in a statement.
